Actively Recruiting
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Led by University of Oklahoma · Updated on 2026-01-26
104
Participants Needed
2
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
CONDITIONS
Official Title
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years old who received anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
- Presence of at least one additional risk factor: previous chest radiation, age over 50, type 2 diabetes mellitus, hypertension, current smoking, obesity (BMI 6 30), previous myocardial infarction, established atherosclerotic heart disease, significant valve disease, or chronic kidney disease
You will not qualify if you...
- Atrial paced heart rhythm
- History of seizure currently on treatment
- History of vasovagal syncope
- End stage liver or kidney disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
2
Stephenson Cancer Center- Tulsa
Tulsa, Oklahoma, United States, 74104
Not Yet Recruiting
Research Team
S
SCC IIT Office
CONTACT
I
Ingrid Block
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here